RELEASE: a protocol for a systematic review based, individual participant data, meta- and network meta-analysis, of complex speech-language therapy interventions for stroke-related aphasia by Brady MC et al.
Aphasiology
ISSN: 0268-7038 (Print) 1464-5041 (Online) Journal homepage: https://www.tandfonline.com/loi/paph20
RELEASE: a protocol for a systematic review based,
individual participant data, meta- and network
meta-analysis, of complex speech-language
therapy interventions for stroke-related aphasia
Marian C. Brady, Myzoon Ali, Kathryn VandenBerg, Linda J. Williams,
Louise R. Williams, Masahiro Abo, Frank Becker, Audrey Bowen, Caitlin
Brandenburg, Caterina Breitenstein, Stefanie Bruehl, David A. Copland,
Tamara B. Cranfill, Marie di Pietro-Bachmann, Pamela Enderby, Joanne
Fillingham, Federica Lucia Galli, Marialuisa Gandolfi, Bertrand Glize, Erin
Godecke, Neil Hawkins, Katerina Hilari, Jacqueline Hinckley, Simon Horton,
David Howard, Petra Jaecks, Elizabeth Jefferies, Luis M. T. Jesus, Maria
Kambanaros, Eun Kyoung Kang, Eman M. Khedr, Anthony Pak-Hin Kong,
Tarja Kukkonen, Marina Laganaro, Matthew A. Lambon Ralph, Ann Charlotte
Laska, Béatrice Leemann, Alexander P. Leff, Roxele R. Lima, Antje Lorenz,
Brian MacWhinney, Rebecca Shisler Marshall, Flavia Mattioli, İlknur Maviş,
Marcus Meinzer, Reza Nilipour, Enrique Noé, Nam-Jong Paik, Rebecca
Palmer, Ilias Papathanasiou, Brigida F. Patricio, Isabel Pavão Martins, Cathy
Price, Tatjana Prizl Jakovac, Elizabeth Rochon, Miranda L. Rose, Charlotte
Rosso, Ilona Rubi-Fessen, Marina B. Ruiter, Claerwen Snell, Benjamin Stahl,
Jerzy P. Szaflarski, Shirley A. Thomas, Mieke van de Sandt-Koenderman,
Ineke van der Meulen, Evy Visch-Brink, Linda Worrall & Heather Harris
Wright
To cite this article: Marian C. Brady, Myzoon Ali, Kathryn VandenBerg, Linda J. Williams,
Louise R. Williams, Masahiro Abo, Frank Becker, Audrey Bowen, Caitlin Brandenburg, Caterina
Breitenstein, Stefanie Bruehl, David A. Copland, Tamara B. Cranfill, Marie di Pietro-Bachmann,
Pamela Enderby, Joanne Fillingham, Federica Lucia Galli, Marialuisa Gandolfi, Bertrand Glize,
Erin Godecke, Neil Hawkins, Katerina Hilari, Jacqueline Hinckley, Simon Horton, David Howard,
Petra Jaecks, Elizabeth Jefferies, Luis M. T. Jesus, Maria Kambanaros, Eun Kyoung Kang, Eman
M. Khedr, Anthony Pak-Hin Kong, Tarja Kukkonen, Marina Laganaro, Matthew A. Lambon Ralph,
Ann Charlotte Laska, Béatrice Leemann, Alexander P. Leff, Roxele R. Lima, Antje Lorenz, Brian
MacWhinney, Rebecca Shisler Marshall, Flavia Mattioli, İlknur Maviş, Marcus Meinzer, Reza
Nilipour, Enrique Noé, Nam-Jong Paik, Rebecca Palmer, Ilias Papathanasiou, Brigida F. Patricio,
Isabel Pavão Martins, Cathy Price, Tatjana Prizl Jakovac, Elizabeth Rochon, Miranda L. Rose,
Charlotte Rosso, Ilona Rubi-Fessen, Marina B. Ruiter, Claerwen Snell, Benjamin Stahl, Jerzy P.
Szaflarski, Shirley A. Thomas, Mieke van de Sandt-Koenderman, Ineke van der Meulen, Evy Visch-
Brink, Linda Worrall & Heather Harris Wright (2020) RELEASE: a protocol for a systematic review
based, individual participant data, meta- and network meta-analysis, of complex speech-language
therapy interventions for stroke-related aphasia, Aphasiology, 34:2, 137-157
To link to this article:  https://doi.org/10.1080/02687038.2019.1643003
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=paph20
© 2019 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group
Published online: 25 Aug 2019.
Submit your article to this journal 
Article views: 4023
View related articles 
View Crossmark data
RELEASE: a protocol for a systematic review based, individual
participant data, meta- and network meta-analysis, of
complex speech-language therapy interventions for
stroke-related aphasia
Marian C. Brady a, Myzoon Ali a, Kathryn VandenBerg a, Linda J. Williams b,
Louise R. Williams a, Masahiro Abo c, Frank Becker d, Audrey Bowen e,
Caitlin Brandenburg f, Caterina Breitenstein g, Stefanie Bruehl h,
David A. Copland f, Tamara B. Cranfill i, Marie di Pietro-Bachmann j,
Pamela Enderby k, Joanne Fillingham l, Federica Lucia Galli m,
Marialuisa Gandolfi n, Bertrand Glize o, Erin Godecke p, Neil Hawkins q,
Katerina Hilari r, Jacqueline Hinckley s, Simon Horton t, David Howard u,
Petra Jaecks v, Elizabeth Jefferies w, Luis M. T. Jesus x, Maria Kambanaros y,
Eun Kyoung Kang z, Eman M. Khedr aa, Anthony Pak-Hin Kong bb,
Tarja Kukkonen cc, Marina Laganaro dd, Matthew A. Lambon Ralph ee,
Ann Charlotte Laska ff, Béatrice Leemann gg, Alexander P. Leff hh, Roxele R. Lima ii,
Antje Lorenz jj, BrianMacWhinney kk, Rebecca Shisler Marshall ll, Flavia Mattioli mm,
İlknur Maviş nn, Marcus Meinzer oo, Reza Nilipour pp, Enrique Noé qq, Nam-
Jong Paik rr, Rebecca Palmer k, Ilias Papathanasiou ss, Brigida F. Patricio tt,
Isabel Pavão Martins uu, Cathy Price vv, Tatjana Prizl Jakovac ww,
Elizabeth Rochon xx, Miranda L. Rose yy, Charlotte Rosso zz, Ilona Rubi-Fessen aaa,
Marina B. Ruiter bbb, Claerwen Snell ccc, Benjamin Stahl ddd, Jerzy P. Szaflarski eee,
Shirley A. Thomas fff, Mieke van de Sandt-Koenderman ggg,
Ineke van der Meulen ggg, Evy Visch-Brink hhh, Linda Worrall f
and Heather Harris Wright iii
aNursing Midwifery and Allied Health Professions Unit, Glasgow Caledonian University, Glasgow, UK;
bUsher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK;
cDepartment of Rehabilitation Medicine, The Jikei University School of Medicine, Tokyo, Japan; dUniversity
of Oslo, Oslo, and Sunnaas Rehabilitation Hospital, Bjørnemyr, Norway; eDivision of Neuroscience &
Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of
Manchester, Manchester Academic Health Sciences Centre, Manchester, UK; fSchool of Health and
Rehabilitation Sciences, The University of Queensland, Brisbane, Australia; gDepartment of Neurology with
Institute of Translational Neurology, University of Muenster, Muenster, Germany; hSchool of Biological
Sciences, University of Manchester, Manchester, UK; iSpecial Education, Eastern Kentucky University,
Richmond, KY, USA; jDivision of Neurorehabilitation, Department of Clinical Neurosciences, University
Hospitals and University of Geneva, Geneva, Switzerland; kSchool of Health and Related Research,
University of Sheffield, Sheffield, UK; lNursing Directorate, NHS Improvement, London, UK;
mNeurorehabilitation Clinic, Neurological Sciences Department, Marche Polytechnic University, Ancona,
Italy; nDepartment of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona,
Italy; oEA 4136 Handicap Activity Cognition Health, University of Bordeaux and Department of Physical
Medicine and Rehabilitation, CHU de Bordeaux, France; pSchool of Medical and Health Sciences, Edith
CONTACT Marian C. Brady m.brady@gcu.ac.uk Nursing, Midwifery and Allied Health Professions Research
Unit, Glasgow Caledonian University, Cowcaddens Road, Glasgow, UK; Honorary Professor, School of Health and
Rehabilitation Sciences, The University of Queensland, Brisbane, Australia
PROSPERO Registration number: CRD42018110947.
Integrated Research Approval System (Project ID 179505Introduction)
APHASIOLOGY
2020, VOL. 34, NO. 2, 137–157
https://doi.org/10.1080/02687038.2019.1643003
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License
(http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any
medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Cowan University, Joondalup, Australia; qInstitute of Health & Wellbeing, University of Glasgow, Glasgow,
UK; rDivision of Language and Communication Science, City, University of London, London, UK;
sDepartment of Speech-Language Pathology, Nova Southeastern University, Fort Lauderdale, FL, USA;
tSchool of Health Sciences, University of East Anglia, Norwich, UK; uSchool of Education Communication
and Language Sciences, Newcastle University, Newcastle-Upon-Tyne, UK; vFaculty of Linguistics and
Literary Studies, Bielefeld University, Bielefeld, Germany; wDepartment of Psychology, University of York,
York, UK; xSchool of Health Sciences (ESSUA) and Institute of Electronics and Informatics Engineering of
Aveiro (IEETA), University of Aveiro, Aveiro, Portugal; yDepartment of Rehabilitation Sciences, Cyprus
University of Technology, Limassol, Cyprus; zDepartment of Rehabilitation Medicine, Kangwon National
University Hospital, Chuncheon, Republic of Korea; aaDepartment of Neurology, Assiut University Hospital,
Assiut, Egypt; bbSchool of Communication Sciences and Disorders, University of Central Florida, Orlando,
FL, USA; ccENT/Department of Phoniatry, Tampere University Hospital, Tampere, Finland; ddFaculty of
Psychology and Educational Science, University of Geneva, Geneva, Switzerland; eeMRC Cognition and
Brain Sciences Unit, University of Cambridge, Cambridge, UK; ffDepartment of Clinical Sciences, Karolinska
Institutet, Danderyd Hospital, Stockholm, Sweden; ggNeurorééducation, Département des Neurosciences
Cliniques, Hôpitaux Universitaires de Genève, Geneva, Switzerland; hhDepartment of Brain Repair and
Rehabilitation, Institute of Neurology, UCL, London, UK; iiDepartment of Speech Language Pathology,
Educational Association Bom Jesus – IELUSC, Santa Catarina, Brazil; jjInstitut für Psychologie, Humboldt
University Berlin, Berlin, Germany; kkDepartment of Psychology, Carnegie Mellon University, Pittsburgh, PA,
USA; llDepartment of Communication Sciences and Special Education, University of Georgia, Georgia, USA;
mmNeuropsychology Unit, ASST Spedali Civili of Brescia, Brescia, Italy; nnDepartment of Speech and
Language Therapy, Anadolu University, Eskişehir, Turkey; ooUQ Centre for Clinical Research, The University
of Queensland, Hertston, Australia; ppDepartment of Speech Therapy, University of Social Welfare and
Rehabilitation Sciences, Tehran, Iran; qqNEURORHB-Hospitales Vithas, Valencia, Spain; rrDepartment of
Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Bundang
Hospital, Seongnam, Republic of Korea; ssDepartment of Speech and Language Therapy, Technological
Educational Institute of Western Greece, Patras, Greece; ttSpeech Therapy Department of Health School of
Polytechnic Institute of Porto, Porto, Portugal; uuLaboratório de Estudos de Linguagem, Faculdade de
Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal; vvWellcome Centre for Human
Neuroimaging, UCL, London, UK; wwDepartment of Speech and Language Pathology, Faculty of Education
and Rehabilitation Sciences, University of Zagreb, Zagreb, Croatia; xxDepartment of Speech-Language
Pathology and Rehabilitation Sciences Institute, University of Toronto, and Toronto Rehabilitation Institute,
Toronto, Canada; yySchool of Allied Health, La Trobe University, Melbourne, Australia; zzInstitut du Cerveau
et del la Moelle épinière, Sorbonne University, APHP, Urgences Cérébro-Vasculaires, Hôpital de la Pitié
Salpêtrière, Paris, France; aaaRehaNova Rehabilitation Hospital and Department of Special Education and
Rehabilitation, University of Cologne, Cologne, Germany; bbbSint Maartenskliniek, Rehabilitation Centre
and Centre for Language Studies, Radboud University, Nijmegen, The Netherlands; cccWarrington Hospital,
Warrington and Halton NHS Foundation Trust, Warrington, UK; dddDepartment of Neurology, Charité
Universitätsmedizin Berlin, Berlin, Germany; eeeUAB Epilepsy Centre, Department of Neurology, University
of Alabama at Birmingham, AL, USA; fffDivision of Rehabilitation & Ageing; School of Medicine, University
of Nottingham, Nottingham, UK; gggRijndam rehabilitation Rotterdam and Erasmus University Medical
Center, Rotterdam, Netherlands; hhhDepartment of Neurology and Neurosurgery, Erasmus University
Medical Center, Rotterdam, Netherlands; iiiCollege of Allied Health Sciences, East Carolina University,
Greenville, SC, USA
ABSTRACT
Background: Speech and language therapy (SLT) benefits people
with aphasia following stroke. Group level summary statistics from
randomised controlled trials hinder exploration of highly complex
SLT interventions and a clinically relevant heterogeneous popula-
tion. Creating a database of individual participant data (IPD) for
people with aphasia aims to allow exploration of individual and
therapy-related predictors of recovery and prognosis.
Aim: To explore the contribution that individual participant char-
acteristics (including stroke and aphasia profiles) and SLT interven-
tion components make to language recovery following stroke.
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Methods and procedures: We will identify eligible IPD datasets
(including randomised controlled trials, non-randomised compar-
ison studies, observational studies and registries) and invite their
contribution to the database. Where possible, we will use meta-
and network meta-analysis to explore language performance after
stroke and predictors of recovery as it relates to participants who
had no SLT, historical SLT or SLT in the primary research study. We
will also examine the components of effective SLT interventions.
Outcomes and results: Outcomes include changes in measures of
functional communication, overall severity of language impairment,
auditory comprehension, spoken language (including naming), read-
ing andwriting frombaseline. Data captured on assessment tools will
be collated and transformed to a standardised measure for each of
the outcome domains.
Conclusion: Our planned systematic-review-based IPD meta- and
network meta-analysis is a large scale, international, multidisciplin-
ary and methodologically complex endeavour. It will enable
hypotheses to be generated and tested to optimise and inform
development of interventions for people with aphasia after stroke.
Systematic review registration: The protocol has been registered
at the International Prospective Register of Systematic Reviews
(PROSPERO; registration number: CRD42018110947)
Background
The recent Cochrane systematic review of speech and language therapy (SLT) for aphasia
after stroke demonstrated the effectiveness of SLT compared to no SLT on measures of
functional communication, expressive language, reading and writing (Brady, Kelly, Godwin,
Enderby, & Campbell, 2016). However, the meta-analyses were restricted to group summary
statistics extracted from randomised controlled trial reports. SLT for aphasia is a highly
complex intervention delivered to a heterogeneous population. Interventions may vary by
theoretical approach, treatment target or delivery mode (computer, volunteer or profes-
sionally facilitated). Therapy regimens may vary in intensity (hours of therapy weekly),
duration (weeks or months over which therapy is delivered) and dosage (total number of
therapy hours delivered). Therapists draw on a variety of delivery models (in isolation or
combination), providers and augmentations (e.g., home-based practice) to develop
a tailored intervention to meet an individual’s rehabilitation and communication needs.
While current stroke guidelines acknowledge the benefits of SLT for people with aphasia
following stroke (2008) evidence of how to optimise interventions has been lacking (RCP
2016). Better outcomes may be associated with higher intensity interventions (up to 15
hours weekly) than lower intensity interventions (up to 5 hours weekly) (Brady et al., 2016)
although this was confounded by significantly higher dropouts in the interventions deliv-
ered at a higher intensity. The situation was complicated further by some indication that
benefits and dropouts may be related to the time since stroke. Differential dropouts (and
benefit) were mainly observed in the context of early recruitment to intervention after
stroke. Those recruited years after stroke did not dropout, but evidence of benefit was
absent (Brady et al., 2016).
Further exploration of these interacting factors within the Cochrane systematic review
methodology was limited by the availability of suitable randomised controlled comparisons,
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limited overlap in outcomes across trials (Wallace et al., 2018) and the availability of data
collected and reported. In conducting the Cochrane review we had access to the individual
participant data (IPD) (n = 323/3002) from a small number of included trials; this facilitated
calculation of group summary statistics and representation of the trials within the review
which would otherwise have been omitted and risked reporting bias.
Conducting the systematic review of relevant records highlighted the long tradition
of reporting IPD in published reports of SLT for aphasia after stroke. We were also aware
of the significant advantages an IPD analysis would afford, including the possibility of
larger sample sizes which would support more reliable statistical analysis and permit
adjustment for confounding variables in predictors of recovery. This stimulated our
interest in the possibility of pooling data for secondary analysis purposes.
The process of systematically gathering IPD for the purpose of secondary analysis is
complex, requiring careful planning to avoid problems and to streamline the research process.
A protocol provides a detailed description of the planned research processes and procedures
which enables comparisons of pre-specified plans with the completed research; highlights
protocol deviations in the reporting of the completed study; supports replication of the
research; ensures early documentation of pre-specified decisions and facilitates adherence
to such decisions throughout the research; reduces the risk of research waste through
unintentional duplication of research activities. Registration of systematic review protocols
is supported by the international PROSPERO database (funded by the National Institute for
Health Research, UK) which profiles a brief summary of a systematic review protocol.
Brief registrations however can fall short of the increasingly detailed descriptions of
complex systematic review protocols required in order to adhere with current reporting
systematic review recommendations such as PRISMA (Moher, Liberati, Tetzlaff, Altman, &
Group, 2009; David; Moher et al., 2015) and relevant extensions for protocols (PRIMSA-P
(Shamseer et al., 2015)), individual participant data (PRISMA-IPD (Stewart, Clarke, Rovers,
Riley, Simmonds, Stewart, Tierney and the PRISMA-IPD Development Group 2015)); complex
interventions (PRISMA-CI Guise, Butler, Chang, Viswanathan, Pigott, Tugwell, and the Complex
Interventions Workgroup 2017); and network meta-analysis (PRISMA-NMA Hutton, Salanti,
Caldwell, Chaimani, Schmid, Cameron, Ioannidis, Straus, Thorlund, Jansen, Mulrow, Catalá-
López, Gøtzsche, Dickersin, Boutron, Altman, Moher 2015). Increasingly, such complex proto-
cols are expanded upon in a journal article which supplements reporting of any findings. Our
protocol describes the planned RELEASE systematic-review-based, IPD meta- and network
meta-analysis of a large scale, international, multidisciplinary aphasia research dataset.
Changes to this protocol will be documented in any subsequent publication.
Aim
We aim to develop a database of IPD to explore the contribution that individual
characteristics (including stroke and aphasia profiles) and SLT intervention components
make to language recovery (reflected in improved performance on measures of lan-
guage) of people with aphasia following stroke. Our proposed analyses will use this
database to explore the following research questions:
(1) What is the pattern of language recovery (functional communication, overall
aphasia severity, spoken language production, auditory comprehension, reading
and writing) for people with aphasia after stroke?
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(2) What are the predictors of language recovery following aphasia?
(3) What are the components of effective aphasia rehabilitation interventions?
(4) Are some interventions (or intervention components) more beneficial for some
participant subgroups (individual, stroke or aphasia characteristics) than others?
Methods
Eligibility criteria
All research study designs with IPD on people with aphasia after stroke are eligible for
inclusion. While data from randomised controlled trial (RCT) designs are preferable in meta-
analysis of IPD which looks at intervention effectiveness, the IPD generated in the context of
other study designs may also contribute to covariate-adjusted analyses of recovery profiles
and predictors of prognosis after stroke (Abo-Zaid, Sauerbrei and Riley, 2012). Thus, we will
employ no study design restrictions to IPD contributions. We will also have no language
restrictions.
Inclusion criteria
We will accept IPD datasets that:
● are collected in the context of a primary research study or clinical register with
relevant ethical approvals in place which are published or unpublished;
● include data on a minimum of 10 people with aphasia after stroke (reflecting the
considerable time required for data preparation and actual IPD contribution);
● include IPD on aphasia severity at a minimum of one time-point (baseline);
● include IPD information on time since stroke (or time since aphasia onset) at first
assessment;
● include IPD on functional language use, overall severity of aphasia, language
expression, auditory comprehension, reading or writing.
Participant populations of relevance to our analysis are (a) participants who had no
SLT (b) participants who may have had historical SLT prior to the primary research and
(c) participants that received SLT in the context of the primary research.
Exclusion criteria
Datasets will be excluded if they include only:
● qualitative IPD;
● non-language data (e.g., response to a stimulus measured in time);
● data at group summary statistics level.
Where a dataset includes participants with aphasia of mixed aetiologies, we will
extract the stroke-specific data only. That stroke-specific IPD dataset will be included if
all other RELEASE eligibility criteria are met.
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Definitions
Speech and language therapy interventions
SLT will be “any targeted practice or rehabilitation tasks that aimed to improve language
or communication abilities, activities, or participation” (Brady et al., 2016), which are
often (but not always) delivered by a speech and language therapist. SLT provided by
others is also eligible for inclusion and we will record the provider for further analysis.
Social support and stimulation
Interventions which provide informal support and stimulation of language in a functional
situation, but do not include therapeutic interventions that aim to improve the participant’s
language impairments, will be considered social support and stimulation interventions.
Conventional SLT
Interventions which are only described as “conventional”, “typical” or “usual” SLT, and
where further intervention details (permitting further categorisation of the SLT
approach) are unreported will be referred to as “conventional SLT”. Equivalent terms
used in the literature may include traditional SLT, standard SLT, typical SLT or “as
directed by the therapist”. We acknowledge that what is considered conventional in
one context may not be directly comparable to conventional SLT in another.
SLT co-interventions
In some cases, a co-intervention may be administrated before, during or after the SLT
intervention. These may include, for example, pharmacological interventions (e.g.,
Levodopa in Breitenstein et al., 2015) or neurostimulation (e.g., transcranial direct current
stimulation in Abo, Kakuda, Watanabe, Morooka, Kawakami, Senoo, 2012). Such co-
interventions are not typically within the remit of routine clinical SLT and examining
their contribution to language recovery is beyond the scope and resources of this study,
but their presence will be noted as will their possible contribution to the analysis.
Information sources
A range of electronic databases will be searched from their inception, including the
Cochrane Stroke Group Trials Register, CENTRAL and other Cochrane Library Databases
(CDSR, DARE, HTA), MEDLINE, EMBASE, CINAHL, AMED, LLBA, and SpeechBITE with
a comprehensive RCT optimised search strategy as used in the relevant Cochrane Review
(Brady et al., 2016). Wewill also review all studies included and excluded from the systematic
review (Brady et al., 2016). We will also search major trials registers including ClinicalTrials.
gov (www.clinicaltrials.gov/), the Stroke Trials Registry (www.strokecenter.org/trials/),
Current Controlled Trials (www.controlled-trials.com), and WHO ICTRP (www.who.int/
ictrp/search/en/). As an example, our MEDLINE search strategy is presented in Appendix 1.
Study records
We will systematically screen all records identified by our search for eligibility and inclusion
in RELEASE. Where eligible datasets are identified, we will invite the primary research teams
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to contribute their dataset to the RELEASE database. We will also extend an invitation to
contribute datasets to members of the Collaboration of Aphasia Trialists (CATs, www.
aphasiatrials.org). Initial project developmentwork involving this network generated several
commitments to contribute to the database in preparation for our funding application.
Selection process
Record titles and abstracts will be screened for eligibility using the criteria listed earlier.
Full-text publications of relevant records will be retrieved where possible and reviewed.
Where published reports are unavailable (for recently completed studies, clinical regis-
tries or similar), we will clarify eligibility in discussion with the primary research team.
Disagreements will be resolved through discussion, where necessary involving an addi-
tional reviewer. Where eligible IPD are available in the public domain we will extract the
data relevant to RELEASE, creating an electronic dataset for use in the study.
Data collection
Where we identify a dataset that is eligible for RELEASE but unavailable in the public
domain, we will approach the relevant data gatekeepers for that dataset and invite them
to contribute the anonymised data to the RELEASE study. Wewill use a systematic approach
to record all communication attempts (in all formats including telephone calls, emails and
other communication formats) in relation to these primary research datasets and associated
teams including queries around eligibility, invitations to contribute and other correspon-
dence. Communication with all external researchers will be consistent; for example, all will
receive a similar number of invitations to contribute data and follow-up invitations.
Where the primary research team expresses interest, we will request that they
contribute a copy of their anonymised electronic dataset in an encrypted format. We
will invite submission of all relevant supporting documents such as a data dictionary,
ethical approval for the primary research, a funder’s report, or other reporting of that
dataset and findings. We will also request evidence of gatekeeper (data controller)
approval to share the dataset with the RELEASE collaborators. Where necessary, if the
primary research team require additional permissions to share the dataset for the
purposes of secondary data analysis, we will request a copy of this.
Data extraction
Using best practices in reporting complex interventions (Hoffmann, Glasziou, Boutron,
Milne, Perera, Moher, Altman, Barbour, Macdonald, Johnston, Dixson-Woods, McCulloch,
Wyatt, Chan, & Michie, S., 2014), we will develop and pilot a data extraction table to support
the collection of relevant data across multiple datasets. Data items extracted are listed
within four main groups in Table 1. All available sources of information on the primary
dataset will be used to populate the table such as published papers and through direct
communication with the primary research team to gather data items unavailable within the
contributed materials. Once data extraction has been completed on a dataset, the primary
research team will be asked to review the data extraction for accuracy and completeness.
For public domain datasets, a second researcher will rigorously double check the
data. Any data items unavailable from the sources described earlier will be considered
either “not applicable” (e.g., details of SLT intervention within a study that does not have
an intervention) or “unreported”.
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Outcomes
Our primary outcome will be change in language recovery profiles according to overall
language ability, auditory comprehension, spoken language production, reading, writ-
ing, and functional communication (Table 1). As RELEASE will undertake secondary
analysis (data synthesis) of data originally gathered in the context of primary research
studies, it is important that we do not pre-specify the language assessment tools eligible
for inclusion. Given the nature of our international, multidisciplinary, multilingual data-
base, we will need to be responsive to emerging datasets. However, measurement tools
included in our analysis will (a) capture the outcomes of relevance to RELEASE, (b) be
published and accessible in the public domain, and (c) be approved by the RELEASE
Collaborators. Screening tools will be excluded, given their typical lack of sensitivity due
to ceiling effects, questionable psychometric properties and the impact this would have
on analysis.
Outcomes of primary importance to people with aphasia and their families typically
include communicative participation and activity (e.g., Enderby & John, 2015; Wallace,
Worrall, Rose, & Le Dorze, 2014). However, these outcomes have historically been
captured infrequently in aphasia research (Brady et al., 2016), though this will change
for future aphasia research with relevant measures included in the recently published
core outcome set for aphasia research (Wallace, Worrall, Rose, Le Dorze, Breitenstein,
Hilari, Babbitt, Bose, Brady Cherney, Copland, Cruice, Enderby, Hersh, Howe, Kelly, Kiran,
Laska, Marshall, Nicholas, Patterson, Pearl, Rochon, Rose, Sage, Small, & Webster 2018).
Table 1. Data extraction items.
Participant characteristics
● Demographic information (e.g., age, sex, handedness, ethnicity)
● Environmental descriptors (e.g., living environment, social support)
● Stroke characteristics (e.g., type, time since stroke, severity, cognition)
Language measure
● Functional communication
● Aphasia ability/severity
● Auditory comprehension
● Spoken language production
● Reading
● Writing
Primary dataset level information
● Design
● Inclusion/exclusion criteria (e.g., dysarthria, prior stroke)
● Recruitment dates (or publication)
● Numbers of participants
● Country and language
● Data collection time-point(s)
SLT Intervention (where relevant)
● Provider
● Delivery mechanism(s)
● Context of intervention
● Duration (total number of days during which therapy was delivered)
● Intensity (hours of therapy provided on a weekly basis)
● Frequency (how many sessions provided weekly)
● Dosage (total number of hours of therapy provided)
● Tailoring (by difficulty, by functional relevance)
● Adherence (data capture and actual adherence rates)
● Theoretical approach
● Treatment target
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Many of the commonly used tools also capture a mix of activity and participation
constructs which would prevent consideration of activity and participation outcomes in
isolation. For this reason, in the context of this secondary analysis research, we will use
the umbrella term “Functional Communication” to accommodate outcome measures
within primary research studies which capture the functional use of language. This will
also facilitate comparisons with the relevant evidence synthesis from the Cochrane
review (Brady et al., 2016). As more researchers adopt the core outcomes set for aphasia
(Wallace et al., 2018), the prevalence of outcome measures reflecting activity and
participation will change.
Methodologically, functional communication measures capture information using
performance-based measures, self- or proxy report, Likert scales, categorical scales,
observational profiles and counts of discourse features. Consequently, data synthesis
may be challenging. If availability and synthesis of this outcome is problematic (less than
20% of IPD data can be synthesised) then we will synthesise as much data as possible,
but we will consider measures of overall language ability (a global measure of language
performance across spoken and written language domains) as an important outcome.
We will extract and use raw scores wherever possible. Percentage scores will be used
to calculate the raw score if possible. Correct or incorrect scoring systems will be aligned
on the same tool and with the same direction of scoring, i.e., all data will be reported in
the same format, all reported as positive or all reported as negative.
Risk of bias of individual studies
We will extract information on the methodological quality of each primary research
dataset included in RELEASE (Aromataris et al., 2015). We will consider the following
potential risks of bias:
● Selection bias: Choice and allocation of individual participants to a specific group. Within
the context of a randomised controlled trial, for example, we will consider whether the
randomisation sequence generated was truly random and whether the sequence alloca-
tion was concealed up to the time of allocation of the individual to a group.
● Performance bias: Differences in co-interventions between groups (in group com-
parison study designs) that were unaccounted for within the intervention compar-
isons. Blinding participants to the delivery of SLT (or not) is unlikely to be achieved
though may be possible in the context of pharmacological interventions or elec-
trical stimulation co-interventions.
● Detection bias: We will document blinding of outcome assessors.
● Attrition bias: We will examine whether there is evidence of systematic between group
differences in the numbers of drop-outs (withdrawals for any reason) or non-adherence
(those that declined to continue study participation during the intervention).
For each potential risk of bias, we will code the studies as low, unclear, or high risk.
We will consider the impact of any potential biases on our findings narratively or using
sensitivity analyses as appropriate.
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Data handling and synthesis
Each contributing primary research dataset will be given a unique identifier while each
constituent participant will have a unique RELEASE ID which will facilitate identification
of each dataset and participant to specific analyses. Datasets will be checked for
duplicate participant datasets through careful review of IPD demographics across all
datasets and reports from the same primary research team and where possible clarify
with the primary researchers. We will avoid the risk of double counting by excluding any
duplicate data from the analysis and reporting.
The included research datasets will be classified by study design and reflecting the
contribution each dataset will make to the proposed analyses as either (a) randomised
controlled trial (RCT); (b) a non-randomised comparative study with two or more groups
but where no randomisation was applied; (c) cohort/case series or (d) registries. We will
carry out various checks on the data, discussing and clarifying discrepancies with the
primary research teams. We will, for example, check the version of an outcome mea-
surement tool used and the range values reported to ensure they are reasonable before
combining the data to create a new master dataset. While some large registries may
have sufficient data to examine some of the RELEASE research questions in isolation,
a minimum of two datasets will be included within any RELEASE meta-analysis. As our
eligibility criteria require a minimum number of 10 IPD in each dataset, the minimum
number of IPD in any meta-analysis will be 20.
Where we identify cross-over datasets, we will extract the data as standard, noting
the cross-over point. Data up to the point of cross-over will likely be included in the
analysis as planned. We will not use data beyond the cross-over point.
For outcomes of relevance to RELEASE, we anticipate that the contributing datasets may
capture relevant outcomes using a range ofmeasurement instruments, including those in or
adapted for any language. In synthesising these data, we will first identify themeasurement
used most commonly across datasets (“anchor measure”) and then profile all the remaining
assessment tools (“minority measures”) used to capture that outcome, the number of
studies that used it and the available IPD, the median score and interquartile range (IQR).
Language or version variations will be treated as different tools. Minority measures will then
be transformed to match the format and range of the anchor instrument of that language
outcome through a method previously used by the Early Breast Cancer Trialists
Collaborative Group (Peto et al., 2012). This process will be repeated for all outcomes.
In order to maintain a semblance of the anchor measure’s distribution, each anchor
measure and related minority measure will be divided into quartiles. A linear transfor-
mation from the minority to the anchor will be applied within each quartile. We
considered but rejected three other major approaches to transformation (normalising,
internal, and direct linear) as they would be difficult to interpret given that the aim of
RELEASE is to examine clinically important changes in score rather than statistically
significant differences. We rejected normalising transformations, such as the Van der
Waerden (1953), on the basis that (i) pooled ranks across the measures would be
impossible due to the varying widths of the scales, and (ii) the “true” value of the
score would be lost. Internal normalising (i.e., standardising within each study) would
also result in the loss of the true value of the scales and suffer the same problems of
interpretability. Direct linear transformation, while maintaining the value of the anchor
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measure and thus some interpretability, would result in the distribution of the minority
measure being mapped on to the anchor measure, and not retaining the distribution of
the anchor measure itself. As scales are often skewed in different directions, this would
impact on the interpretability of the results.
All variables of interest will be synthesised (Table 1) across contributing primary
research datasets. A master data dictionary and decision tree will be developed and
maintained to document all synthesis decisions to ensure consistency in the treatment
of data items and adherence to Collaboration-wide consensus decisions. For example,
stroke lesion types will be recorded as either ischaemic (reflecting the terms infarct,
lacuna, thrombosis or embolism) or haemorrhage (hematoma, intracranial haemorrhage
or mixed stroke) where possible. The decision tree will also function to describe in detail
all contributing language assessment tools thus allowing us to use the overall aphasia
severity assessment summary score and to consider the contribution specific language
subtests (e.g., naming) may make to other aspects of our planned analyses.
Attempts will be made to extract any missing data which is unavailable within
a dataset from alternative sources including all associated published papers or reports,
unpublished materials or (where possible) requesting the data from the primary research
team. If this data remains unavailable, we will record as appropriate that it is unreported,
or missing, and we will examine all missing data for patterns of loss or whether the data
is missing completely at random. Variables with data not missing completely at random
will be excluded from our analysis. Where more than 20% of data is missing from
a primary research dataset’s variable, that dataset’s variable will be excluded from the
meta-analyses. We anticipate that few contributing datasets will include all variables of
interest to our analyses. In such situations, our analyses will be restricted to the subset of
datasets with data on the variable. Where there is less than 20% missing data, patterns
of missingness will be examined to ensure data is missing completely at random. This
will be achieved by coding the variable with missing data as “missing” or “not missing”
and then comparing this variable to demographic variables that may be expected to
have some impact on recording (e.g., participant’s age, sex, type of stroke).
We will test for the randomness of missing data (in order to exclude the possibility of
bias) by coding the variable with missing data as “missing” or “not missing”. We will then
compare this variable to demographic variables that may be expected to have some
impact on recording (e.g., participant’s age, sex, type of stroke) and categorical variables
will be compared with the χ2 test. Depending on the normality of the data distribution,
we will compare continuous variables using the t-test or Mann–Whitney U test.
Sensitivity and subgroup analysis
The impact of any data synthesis decisions on the findings will be considered by conducting
a series of sensitivity analyses. Amongst the planned sensitivity analyses will be an exploration
of the impact of the choice of assessment tool included in the data syntheses. If a dataset has
employed two or more assessment tools eligible for synthesis within a language outcome (in
the absence of any other deciding criteria, such as number of records or presence of follow-up
data), the assessment most commonly used across the RELEASE database will go forward to
the data synthesis and the impact of that choice will be investigated in a sensitivity analysis.
We will also consider the findings based on the anchor measures alone, and what impact
exclusion of the minority measures would have had on the findings.
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A key decision in any meta-analysis is whether to use a random or fixed effect model
in the meta-analysis. Standard errors for random effects models are more efficient, and
thus random effects models should be used in preference to fixed effects models (Wu,
1973). The Wu–Hausman test will be used to review the two possible approaches to the
meta-synthesis of the data using either a random effect or fixed effect model, to assess
whether the effects are consistent and do not preclude the use of random effects.
Possible bias due to the availability of historic datasets or changes in clinical practices
will be assessed by excluding older datasets (for example, with a last participant
recruitment date of 1999 or earlier) from the analysis. As it is possible, or even likely,
that response to treatment will depend on time since stroke and stroke severity,
subgroup analyses of these variables will also be undertaken in addition to being
included as covariates in the modelling process. Further subgroups may be identified
as the analysis is conducted and will be explored appropriately.
We anticipate that SLT will typically have been described at the primary research study or
group level and only rarely (if ever) at IPD level within an electronic dataset. SLT intervention
data will be extracted fromnarrative descriptions in the primary research protocol, report, or
in communication with the primary research team. We have worked closely with RELEASE
collaborators to define and categorise therapy approaches in preparation for meaningful
synthesis and analysis (Rose et al., 2018; Table 2) and all SLT interventions will be combined
into these (and if required, additional) clusters for analysis.
Meta-biases
In the section above, Risk of bias of individual studies, we detailed how we would consider
the risk of bias within the individual studies contributing to RELEASE. In this section, we
Table 2. Therapy categories.
Therapy approach defined by treatment target
Mixed SLT: SLT targets both auditory comprehension and spoken language production impairments.
Auditory Comprehension SLT: SLT targets rehabilitation of auditory comprehension.
Word Finding SLT: SLT targets rehabilitation of word retrieval or naming.
Reading comprehension SLT: SLT targets rehabilitation of reading comprehension.
Writing SLT: SLT targets rehabilitation of written language expression.
Therapy approach defined by theoretical approach
Functional or Pragmatic SLT: Therapy targets improvement in communication activities and tasks considered to be
useful in day-to-day functioning, and often involves targeted practice of real-world communication situations.
Phonological SLT: Therapy uses phonological approaches. It seeks to improve the sound structure of language by
targeting improvements in the phonological input and output routes.
Semantic SLT: Therapy uses semantic approaches which focus on interpretation of language with the aim of
improving semantic processing.
Semantic and Phonological SLT: Employs treatment programme which uses both semantic and phonological
approaches.
Constraint Induced Aphasia Therapy: Participants are required to use spoken communication alone. Other
communicative methods such as gesture are not encouraged or permitted.
Multimodal Therapy (to improve verbal communication): Participants are encouraged to use one or more non-verbal
modality (such as gestures) to facilitate improvements in their spoken language abilities.
Multimodal Therapy (to improve total communication): Participants are supported to use non-verbal channels of
communication alongside or as an alternative to spoken language production or writing in communication.
Melodic Intonation Therapy: Employs rhythm and formulaic language to support recovery of language and
exaggerated melodic sentence patterns to elicit spontaneous speech.
Conversational Partner Training SLT: Targets communication interaction between the person with aphasia and their
conversation partner(s). Conversational partners may be spouse, family member, friends or healthcare
professionals.
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consider all potential sources of bias in how we conduct our proposed IPD meta-analysis
and the steps we will take to reduce risks of bias in our planned meta-analyses.
● Publication bias: Our rigorous approach to the identification and selection of
eligible IPD datasets will identify datasets that were unpublished, reported in the
grey literature, and conducted or reported in any language, thus reducing the risk
of publication bias. Where there are enough datasets making the same compar-
isons, we will explore the potential risk of publication bias using funnel plots.
Where a funnel plot is not possible due to limitations on the availability of similar
datasets, we will explore the risk of publication bias by tabulating the individual
datasets and examining the distribution between the ranges of sample size and the
proportion of studies reporting significant and non-significant findings. Exploration
of publication bias will not be possible in the context of registry datasets.
● Selection bias: We will incorporate a systematic review component as the first stage
to building our IPD database, actively invite dataset contributions from primary
research teams that were not previous collaborators, and extract IPD reported in
the public domain and the grey literature.
● Availability bias: While we will be as inclusive as possible, some current or historic
datasets may remain unavailable where the primary research teams cannot be
contacted, no longer have data access, or may still be reporting their data.
● Other biases: We will consider other possible sources of bias including comparison
choice bias or potential carryover of treatment effects within cross-over datasets.
We will review the relevance of the primary research study’s objectives as eligible
datasets may not have been gathered in the context of a research study with
a focus on language recovery or rehabilitation.
Statistical analyses
The data will be analysed using the SAS v9.4 PROCMIXED, with the outcome as change from
baseline (absolute numerical or percentual depending on the planned analysis) with study
as a random effect. We anticipate that many of the included datasets will be small (10 IPD
minimum) and so the inclusion of the random intercepts for individual patients would be at
risk of failures of the model to resolve. Thus, we chose not to include them.
Progression of aphasia recovery, stratified by domain of assessment
We will describe the progression of aphasia recovery using two approaches: first, we will
examine language performance at a single time point (a snapshot). We will examine the
distribution of language domains of interest at the first assessment (baseline or time 0)
within each dataset. At this time-point, participants will not have received any study-
mandated intervention, having only completed a baseline assessment, and may have
been enrolled into the study at any time-point since index stroke. This will allow us to
generate an overview of language impairment across domains of interest, at time 0 for all
participants, where time 0 can range from index stroke, up until decades after index stroke.
Graphs of baseline transformed outcome measure scores over time, and stratified by time
since stroke, age, sex and living context, will also be generated to examine the contribution
that these potential confounders make to the language scores at each baseline time-point.
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Our second approachwill examine the trajectory of language impairment progression over
all domains of interest by examining the absolute change in each domain score since baseline,
and the rate of change of each score over time. We will stratify our observations by SLT
allocations: 1) No study-mandated SLT, and no receipt of historical SLT; 2) no study-mandated
SLT, but participant may have received historical SLT; and 3) study-mandated SLT.
We will attempt to fit simple linear regressions, with the option of splitting by time
period since index stroke if it appears necessary.
Identifying predictors of language recovery and components of effective
intervention
IPD on stroke profile, demographic characteristics and living context at baseline and
(when available) follow-up time-points will be extracted. We will explore the data graphi-
cally and using summary statistics. The effect of time will be considered by (a) the time
since stroke as an absolute measure of the transformed scores; and (b) time since baseline,
using change from baseline. Change from baseline was selected as the outcome measure
due to it being a more meaningful outcome for people with aphasia and clinicians, rather
than a standardised measure (The Stroke Association, 2019; Cochrane Handbook for
Systematic Reviews of Interventions; Wallace, Worrall, Rose, LeDorze, Cruice, Isaksenm
Kong, Simmons-Mackie, Scarinci & Gauvreau 2017). Where residuals are normally distrib-
uted (once adjusted for baseline score) they will not fail the basic assumption of a linear
(mixed model) regression.
Intervention details for each study that includes an SLT intervention targeting aphasia
rehabilitation will be recorded in a data extraction table alongside descriptive informa-
tion on the study, the participant characteristics and outcome data. Where studies are
similar in their participants and the type of intervention delivered, and where suitable
language measurement data is reported before and after the intervention, we will pool
the data within a meta-analysis.
Demographic and stroke covariates identified as statistically significant will be used to
create our planned model for analysis. These statistically significant covariates in the
basic model will be treated as a fixed effect along with study as the random effect, then
each of the other covariates of interest will be added to the basic model for examination
of its effect on the adjusted data.
This will allow us to account for differences in participant characteristics before any
treatment variables are examined for influence on the outcome variables. The principal
analysis method will be a mixed effects model, with the primary research study as the
random effect.
Our preference will be to extract data on all components of therapy regimen (for
example, frequency, duration, dosage, duration; Table 1, SLT intervention) wherever
possible as an actual numerical variable. We anticipate that in some datasets this data
will be recorded as IPD while in other cases it will be recorded at the group level as an
intervention protocol. However, while we will initially consider these data on a continuum,
we are also prepared to use categorical variables which will allow further exploration of
these components in a meaningful way. These further analyses will be informed by the
findings of earlier questions and will control for any important factors. For example,
timing, intensity, frequency, duration and dosage of an intervention will be analysed as
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continuous variables or, if the data fall into natural categories, as categorical variables.
Other aspects of therapy will be considered as present or not present. These include
augmentation of dose with prescribed home-based practice and tailoring of an interven-
tion by difficulty or functional relevance.
Network meta-analysis
Network meta-analysis approaches are a specific approach to meta-analysis which allows
for an estimate of the difference between direct and indirect comparisons. For example,
one study compares treatment A with treatment B; and another study compares treat-
ment A with treatment C. Using a network meta-analysis approach the data from these
studies can be combined to compare A versus B and A versus C (direct comparisons) but
can also give an estimate of treatment B versus C (indirect comparison).
We will compare a range of SLT interventions (for example, semantic approaches to
SLT compared to phonological approaches). We will also examine impairment-based
and activity/participation-based approaches. Based on our previous consensus work
(Rose et al., 2018). we will consider three therapy perspectives:
(a) the role of the intervention within the study design (e.g., usual care or social
support as a comparison control versus therapy as the experimental intervention);
(b) Therapy approach defined by impairment target (e.g., rehabilitation of spoken
language production); and
(c) therapy defined by a theoretical approach (e.g., constraint induced aphasia therapy).
We do not plan to explore the broad groupings of SLT or social support as we have
already addressed these questions at group summary statistics level (Brady et al., 2016).
IPD network-meta-analysis
Previous aphasia meta-analysis and network meta-analysis have typically used group-
level aggregated summary statistics to provide a helpful overview of the evidence (e.g.,
Bhogal, Teasell, and Speechley, 2003; Brady et al., 2016). However, this approach also
carries a risk of ecological bias and confounding. RELEASE aims to use pre-existing IPD to
explore some of the differences in the delivery of therapy components (SLT Intervention
in Table 1) in relation to specific participants’ profiles and language recovery. A large
aphasia IPD dataset will permit exploration of the highly heterogeneous nature of
aphasia after stroke, individual level covariates’ influence on SLT treatment effects across
language domains and to control for individualistic predictors. Feasibility will be con-
tingent on the number of trials and IPD available, as well as whether any of the
treatment aspects are predictors of improvement.
An IPD network meta-analysis can be undertaken using either a one or two-stage
approach. A two-stage approach is similar to a standard meta-analysis approach; first,
the IPD is processed centrally, aggregate data is generated for each dataset contributed
(instead of using the primary research team’s reported summary statistics) and then the
aggregated data is meta-analysed. This approach can, however, lead to bias in effects,
greater heterogeneity and lower power to detect associations between language out-
comes and continuous variables (Debray et al., 2018).
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A one-stage IPD network meta-analysis approach combines all available IPD from
across all datasets. In the context of RELEASE, the datasets will have been contributed by
the primary research teams or will have been extracted from the public domain. The
relevant data items are then selected for each planned analysis and put into a single
model. A key methodological benefit of this approach is that confounding can be
addressed as the impact of several (participant and language) variables on an interven-
tion effect can be examined at the same time. The RELEASE study will adopt a one-stage
network meta-analysis approach.
Confidence in cumulative evidence
We will review the quality of the data contributing to our analyses and consider the
impact it may have on the confidence we have in the cumulative results. Where appro-
priate we will apply grading of recommendations, assessments, development and evalua-
tion (GRADE) approaches (Guyatt, Oxman, Schunemann, Tugwell, & Knottnerus, 2011) or
similar tools to reach a judgement about the quality of evidence on our findings.
Discussion
We plan to undertake an IPD meta-analysis and network meta-analysis to explore
language recovery and the effects of specific SLT approaches on aphasia and prognostic
factors. We anticipate that this project will serve to highlight areas of greater certainty as
well as uncertainty in relation to language recovery and components of effective
rehabilitation for aphasia after stroke. Continuing gaps in our knowledge will assist in
prioritising future aphasia research and the design of those research activities. Our
findings will also be useful to clinicians, who need evidence-based guidance to offer
and tailor interventions to their clients’ needs. In addition, the project will highlight the
importance of high-quality design and reporting of participant demographics, prognos-
tic factors and intervention details in the context of aphasia after stroke. RELEASE will
also generate a legacy database which will be supported in the future by the wider
Collaboration of Aphasia Trialists who will moderate access to this resource.
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Appendix 1. MEDLINE search strategy
MEDLINE (Ovid) from 1946 to 22 September 2015
1. exp aphasia/
2. language disorders/or speech disorders/or anomia/
3. (aphasi$ or dysphasi$ or anomia or anomic).tw.
4. ((speech or language$ or linguistic or communicat$) adj5 (disorder$ or impair$ or problem$ or
dysfunction or difficult$)).tw.
5. 1 or 2 or 3 or 4
6. exp aphasia/rh, th or language disorders/rh, th or speech disorders/rh, th or anomia/rh, th
7. speech-language pathology/or exp “rehabilitation of speech and language disorders”/
8. ((speech or language$ or linguistic or aphasi$ or dysphasi$ or anomia or anomic) adj5 (therap$
or train$ or rehabilitat$ or treat$ or remediat$ or intervention$ or pathol$)).tw.
9. (SLT or SLP).tw.
10. (melodic intonation therap$ or MIT).tw.
11. 6 or 7 or 8 or 9 or 10
12. Randomized Controlled Trials as Topic/
13. random allocation/
14. Controlled Clinical Trials as Topic/
15. control groups/
16. clinical trials as topic/or clinical trials, phase i as topic/or clinical trials, phase ii as topic/or
clinical trials, phase iii as topic/or clinical trials, phase iv as topic/
17. double-blind method/
18. single-blind method/
19. Placebos/
20. placebo effect/
21. cross-over studies/
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22. randomized controlled trial.pt.
23. controlled clinical trial.pt.
24. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial
phase iv).pt.
25. (random$ or RCT or RCTs).tw.
26. (controlled adj5 (trial$ or stud$)).tw.
27. (clinical$ adj5 trial$).tw.
28. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
29. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
30. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
31. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
32. (cross-over or cross over or crossover).tw.
33. (placebo$ or sham).tw.
34. trial.ti.
35. (assign$ or allocat$).tw.
36. controls.tw.
37. or/12–36
38. 5 and 11 and 37
39. exp animals/not humans.sh.
40. 38 not 39
41. (pediatric or paediatric or infant or infants or child or children$ or childhood or neonat$ or
juvenile$ or toddler$).ti.
42. (child/or child, preschool/or adult children/or adolescent/or exp infant/) not exp adult/
43. 41 or 42
44. 40 not 43
40. 36 not 39
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